Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP.

J Virol. 2002 Jul;76(14):7293-305.

2.

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR.

J Virol. 2002 Jul;76(14):7306-21.

3.

An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.

Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y.

J Virol. 2008 Jul;82(13):6447-57. doi: 10.1128/JVI.00412-08.

4.

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H.

J Virol. 1996 Feb;70(2):1100-8.

5.

A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.

Luallen RJ, Fu H, Agrawal-Gamse C, Mboudjeka I, Huang W, Lee FH, Wang LX, Doms RW, Geng Y.

J Virol. 2009 May;83(10):4861-70. doi: 10.1128/JVI.02537-08.

8.

Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.

Hoorelbeke B, Huskens D, Férir G, François KO, Takahashi A, Van Laethem K, Schols D, Tanaka H, Balzarini J.

Antimicrob Agents Chemother. 2010 Aug;54(8):3287-301. doi: 10.1128/AAC.00254-10.

9.

Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.

Pashov A, MacLeod S, Saha R, Perry M, VanCott TC, Kieber-Emmons T.

Glycobiology. 2005 Oct;15(10):994-1001.

PMID:
15917430
10.

Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.

Yang Q, Li C, Wei Y, Huang W, Wang LX.

Bioconjug Chem. 2010 May 19;21(5):875-83. doi: 10.1021/bc9004238.

11.

Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.

Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D.

Virology. 2007 Apr 10;360(2):294-304.

12.

Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.

Hong PW, Nguyen S, Young S, Su SV, Lee B.

J Virol. 2007 Aug;81(15):8325-36.

13.

Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.

Doores KJ, Fulton Z, Huber M, Wilson IA, Burton DR.

J Virol. 2010 Oct;84(20):10690-9. doi: 10.1128/JVI.01110-10.

16.
17.

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13372-7.

18.
19.
20.

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.

Virology. 2003 Sep 1;313(2):387-400.

Supplemental Content

Support Center